Raphael Thys
Image courtesy of Eko Health.
Eko Health, the California-based healthcare technology company known for its advanced stethoscopes, has raised $41 million in Series D financing. Investors in the round included ARTIS Ventures, Highland Capital Partners, NTTVC and Questa Capital.
Eko plans to put the funds toward expanding access to its stethoscope technology both in the United States and abroad. Now that the company has gained U.S. Food and Drug Administration approval for its artificial intelligence (AI) algorithms focused on structural heart murmurs and low-ejection fraction, it aims to reach as many patients with the AI-powered devices as possible.
“Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere,” Connor Landgraf, CEO and co-founder of Eko Health, said in a prepared statement. “Just as Ring transformed doorbells into home security systems, Eko has reinvented the world's most ubiquitous medical tool into a powerful early disease detection platform, creating the world's largest install base of professional AI-enabled cardiology devices.”
“Eko has spent the past decade building an unparalleled dataset of digital heart and lung sounds, which it leverages to develop clinical AI for the physical world,” added Vas Bailey, PhD, chair of the board at Eko Health and a partner at ARTIS Ventures. “Like countless others, I lost a parent much too early to undetected heart disease. I am deeply inspired by the team's dedication to saving lives by equipping hundreds of thousands—and soon millions—of clinicians worldwide with our groundbreaking early detection platform.”
Spurred by new working relationships with investors, Eko is specifically interested in expanding its reach among patients in Singapore and South Korea.